Trial reportThe Journal of allergy and clinical immunology2023
Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.
Trial report in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Pooled it
- Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study.Pharmacotherapy · 2026Observational
- Global Prevalence of Asthma in Adults with Atopic Dermatitis and the Atopic Dermatitis-Asthma Association.Pharmaceuticals (Basel, Switzerland) · 2026Review
- TDP-43 promotes allergen-induced inflammation and influenza A virus replication in airway epithelium.Nature communications · 2026Article
- Precision medicine in asthma: endotype stratification, biomarker-guided biologics, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Respiratory Biologics Utilization, Prescription Predictors, and Outcomes in Patients With Asthma and Comorbid Overweight or Obesity.The journal of allergy and clinical immunology. In practice · 2026Observational
- Population-Level Trends in Asthma Exacerbations After Introduction of Respiratory Biologics.JAMA network open · 2026Article
- The Role of and Therapeutic Strategies for Eosinophils in Atopic Dermatitis.Biomedicines · 2026Review
- B cell activating factor (BAFF) levels are associated with failed remission after 12 months of treatment with benralizumab and mepolizumab in severe asthma.Respiratory research · 2026Article
- Emerging Therapeutic Strategies in Asthma: Advances in Treatment, Drug Delivery, Drug Adherence, and Disease Management.Current allergy and asthma reports · 2026Review
- Triggering mechanisms of acute thunderstorm asthma: epithelial barrier disruption and immune dysregulation.Respiratory research · 2026Review
- Comparative effectiveness of biologics in lung function improvement among patients with severe asthma: a real-world study.Respiratory research · 2026Article
- Design and Implementation of Observational Studies Emulating a Target Trial.JAMA network open · 2026Article
- Biologics for Children and Adolescents with Asthma: A Systematic Review and Exploratory Indirect Comparative Analysis.Journal of asthma and allergy · 2026Review
- Comparative effectiveness of omalizumab in asthma-COPD overlap vs. asthma: a retrospective cohort study.Frontiers in medicine · 2026Article
- Unveiling Interleukin-40: A Novel Regulator of Macrophage and B Cell Function in Allergic Asthma.International journal of biological sciences · 2026Article
- Emerging immune networks and targeted strategies in T2 asthma.Frontiers in immunology · 2026Review
- Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE.ERJ open research · 2025Article
- Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study.Research and practice in thrombosis and haemostasis · 2025Article
- Safety and Efficacy of Dupilumab, Omalizumab, and Mepolizumab in Moderate-to-Severe Asthma: A Systematic Review.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMultiple mAbs are currently approved for the treatment of asthma. However, there is limited evidence on their comparative effectiveness.
objectiveOur aim was to compare the effectiveness of omalizumab, mepolizumab, and dupilumab in individuals with moderate-to-severe asthma.
methodsWe emulated a hypothetical randomized trial using electronic health records from a large US-based academic health care system. Participants aged 18 years or older with baseline IgE levels between 30 and 700 IU/mL and peripheral eosinophil counts of at least 150 cells/μL were eligible for study inclusion. The study period extended from March 2016 to August 2021. Outcomes included the incidence of asthma-related exacerbations and change in baseline FEV
resultsIn all, 68 individuals receiving dupilumab, 68 receiving omalizumab, and 65 receiving mepolizumab met the inclusion criteria. Over 12 months of follow-up, 31 exacerbations occurred over 68 person years (0.46 exacerbations per person year) in the dupilumab group, 63 over 68 person years (0.93 per person year) in the omalizumab group, and 86 over 65 person years (1.32 per person year) in the mepolizumab group (adjusted incidence rate ratios: dupilumab vs mepolizumab, 0.28 [95% CI = 0.09-0.84]; dupilumab vs omalizumab, 0.36 [95% CI = 0.12-1.09]; and omalizumab vs mepolizumab, 0.78 [95% CI = 0.32-1.91]). The differences in the change in FEV
conclusionsAmong patients with asthma and eosinophil counts of at least 150 cells/μL and IgE levels of 30 to 700 kU/L, dupilumab was associated with greater improvements in exacerbation and FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.